1. Home
  2. CRDL vs SRL Comparison

CRDL vs SRL Comparison

Compare CRDL & SRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • SRL
  • Stock Information
  • Founded
  • CRDL 2017
  • SRL 2017
  • Country
  • CRDL Canada
  • SRL China
  • Employees
  • CRDL N/A
  • SRL N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • SRL Professional Services
  • Sector
  • CRDL Health Care
  • SRL Consumer Discretionary
  • Exchange
  • CRDL Nasdaq
  • SRL Nasdaq
  • Market Cap
  • CRDL 104.5M
  • SRL 122.8M
  • IPO Year
  • CRDL N/A
  • SRL N/A
  • Fundamental
  • Price
  • CRDL $1.23
  • SRL $7.90
  • Analyst Decision
  • CRDL Strong Buy
  • SRL
  • Analyst Count
  • CRDL 3
  • SRL 0
  • Target Price
  • CRDL $9.00
  • SRL N/A
  • AVG Volume (30 Days)
  • CRDL 298.3K
  • SRL 18.7K
  • Earning Date
  • CRDL 11-14-2024
  • SRL 12-31-2024
  • Dividend Yield
  • CRDL N/A
  • SRL 12.97%
  • EPS Growth
  • CRDL N/A
  • SRL N/A
  • EPS
  • CRDL N/A
  • SRL N/A
  • Revenue
  • CRDL N/A
  • SRL $33,997,735.00
  • Revenue This Year
  • CRDL N/A
  • SRL N/A
  • Revenue Next Year
  • CRDL N/A
  • SRL N/A
  • P/E Ratio
  • CRDL N/A
  • SRL N/A
  • Revenue Growth
  • CRDL N/A
  • SRL N/A
  • 52 Week Low
  • CRDL $0.96
  • SRL $5.74
  • 52 Week High
  • CRDL $3.12
  • SRL $9.99
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 35.88
  • SRL 51.64
  • Support Level
  • CRDL $1.17
  • SRL $7.93
  • Resistance Level
  • CRDL $1.30
  • SRL $8.39
  • Average True Range (ATR)
  • CRDL 0.08
  • SRL 0.66
  • MACD
  • CRDL 0.00
  • SRL 0.00
  • Stochastic Oscillator
  • CRDL 17.65
  • SRL 43.51

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

Share on Social Networks: